We are pleased to have published results from our Phase 1 MAD study of MBX 2109 in JCEM, a leading peer-reviewed journal of endocrine and metabolic research,” said Kent Hawryluk, President and Chief ...

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical ...

The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule ...

Analysts initiated coverage on Septerna, Inc. with Overweight ratings and price targets of $50 and $38. SEPN's innovative ...

Moreover, the lead product, SEP-786, shows promise as a convenient oral alternative to existing injectable treatments for hypoparathyroidism. The preclinical results have been impressive, showing ...

Entera's proprietary N-Tab™ platform consistently delivered across our oral GLP-2 tablet, oral GLP-1/Glucagon tablet and ...